Summary
The FDA has sent the makers of the cholesterol pill Crestor notice that the agency finds some ads for the drug misleading. Regulators say Crestor is not necessarily, as the ads claim, the best of its class of drugs known as statins. An FDA official notes that 80 milligrams of Crestor's main competitor Lipitor is just as effective as a 40 milligram dose of Crestor.
Original source:
http://www.forbes.com/technology/2005/03/11/cx_mh_0311azn.html
Details
For the second time in four months, the Food and Drug Administration's Division of Drug Marketing, Advertising, and Communications (DDMAC) has warned AstraZeneca on advertisements promoting its cholesterol drug Crestor--calling suggestions that the drug is better that Pfizer's Lipitor "misleading."
A spokesperson for AstraZeneca (nyse: AZN - news - people) said the letter, a copy of which was obtained by Forbes.com, only applies to one ad campaign in the context of one specific portion of data from one study.
AstraZeneca continues to believe that based on other comparative data it will be able to claim that Crestor is better at lowering bad cholesterol than all other statins.
In a letter sent to AstraZeneca, an officer at DDMAC noted that the efficacy of Crestor's top 40-milligram dose was similar to that of 80 milligrams of Lipitor in the study referenced by AstraZeneca.
"The TV and print ads make false or misleading claims regarding the superiority of Crestor," Christine Smith, a regulatory review officer at DDMAC wrote in the letter.
"All cholesterol drugs simply aren't the same," one ad intoned, according to the letter.
Print advertisements made their own rhyming claims.
If not then compare," says a third.
Pfizer's (nyse: PFE - news - people) Lipitor rules the cholesterol market and is prescribed more than all other similar drugs combined.
Merck (nyse: MRK - news - people) and Schering-Plough (nyse: SGP - news - people) have introduced their own drug, Vytorin, which gets efficacy by combining Merck's Zocor with another cholesterol-lowering drug.
Crestor, meanwhile, has been faced with critics who say it may not be as safe as its competitors--claims with which AstraZeneca and some researchers vigorously disagree but which have had a noticeable affect on sales.
About the author: Mike Adams is a consumer health advocate and award-winning journalist with a passion for sharing empowering information to help improve personal and planetary health He has authored more than 1,800 articles and dozens of reports, guides and interviews on natural health topics, and he has authored and published several downloadable personal preparedness courses including a downloadable course focused on safety and self defense. Adams is an honest, independent journalist and accepts no money or commissions on the third-party products he writes about or the companies he promotes. In 2010, Adams launched TV.NaturalNews.com, a natural health video site featuring videos on holistic health and green living. He also launched an online retailer of environmentally-friendly products (BetterLifeGoods.com) and uses a portion of its profits to help fund non-profit endeavors. He's also a veteran of the software technology industry, having founded a personalized mass email software product used to deliver email newsletters to subscribers. Adams volunteers his time to serve as the executive director of the Consumer Wellness Center, a 501(c)3 non-profit organization, and practices nature photography, Capoeira, martial arts and organic gardening. Known by his callsign, the 'Health Ranger,' Adams posts his missions statements, health statistics and health photos at www.HealthRanger.org
Have comments on this article? Post them here:
people have commented on this article.
Tuesday, March 22, 2005
Email this article to a friend
Share
this article on: 
